Search PubMed⌕ Search

Biomedical subjects

L Gecelter

Publications and source records attributed to L Gecelter.

15 recordsLinked to original sources
PubMed1977

Colocystoplasty.

Explore the source record for details and available documents.

Adenocarcinoma↗
PubMed1975

Pituitary gonadotropin response to luteinizing hormone-releasing hormone (LH-RH) in males with azo- and oligospermia.

Twenty-one males with azo- or oligospermia presenting with infertility and with no evidence of organic disease were studied with luteinizing hormone - releasing hormone (LH-RH). A pituitary luteinizing hormone (LH) and follicle stimulating hormone (FSH) response was present in all cases and was normal in the majority of the subjects. Serum testosterone and 17 beta estradiol levels were normal in all cases studied. No significant correlations were found between the gonadotropin estimations and sperm count, basal serum testosterone or testosterone response to human chorionic gonadotropin. It is concluded that LH-RH is of limited diagnostic use in the investigation of this group of patients with male infertility and provides no further insight into the pathogenesis of this condition.

Adult↗
PubMed1970

Tissue typing, antilymphocyte globulin, and prophylactic graft irradiation in cadaver kidney transplantation.

In a series of 27 recipients of cadaver kidney grafts, 26 were at the time of writing alive, 3 to 25 months after transplantation, and 25 patients were alive with functioning first grafts. The one-year patient survival in 18 patients was 94% and the one-year graft survival was 89%. There was no beneficial correlation between tissue matching and the frequency of major early rejection episodes or graft function 12 or more months after transplantation. Antilymphocyte globulin administration was associated with a lower incidence of early rejection episodes, but this was not statistically significant. A combination of prophylactic graft irradiation and antilymphocyte globulin administration for at least the first two weeks was associated with a significantly reduced frequency of major early rejection episodes and appreciably better graft function at 12 months. This effect could not be ascribed to better tissue matching.

Antilymphocyte Serum↗